Trial Outcomes & Findings for Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI (NCT NCT02225106)

NCT ID: NCT02225106

Last Updated: 2019-11-15

Results Overview

Relationship between tonic DA release (assessed by displacement of \[11C\] raclopride by oral methylphenidate) and improvement in processing speed after 4 weeks of treatment with oral methylphenidate. The Perceptual organization and processing speed index is measured from the Digit Symbol and Symbol Searches from the Weschler Adult Intelligence Scale (WAIS-IV). The tasks that comprise the PSI, (Coding, Symbol Search), are timed and require attending to visual material, visual perception and organization, visual scanning, and hand-eye coordination. It is a standardized scale were 100 is the mean of a normal population, and each 10 points represents 1 standard deviation above or below the mean. Thus, an index of 110 is 1 SD above the mean, 90 is 1 SD below the mean.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

11 participants

Primary outcome timeframe

4 weeks

Results posted on

2019-11-15

Participant Flow

Participant milestones

Participant milestones
Measure
Open Label Methylphenidate Treatment
Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily. Methylphenidate: Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
Overall Study
STARTED
11
Overall Study
COMPLETED
11
Overall Study
NOT COMPLETED
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Open Label Methylphenidate Treatment
n=11 Participants
Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily. Methylphenidate: Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
11 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
33 years
n=99 Participants
Sex: Female, Male
Female
3 Participants
n=99 Participants
Sex: Female, Male
Male
8 Participants
n=99 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
Race (NIH/OMB)
Asian
0 Participants
n=99 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=99 Participants
Race (NIH/OMB)
White
10 Participants
n=99 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
Region of Enrollment
United States
11 participants
n=99 Participants

PRIMARY outcome

Timeframe: 4 weeks

Relationship between tonic DA release (assessed by displacement of \[11C\] raclopride by oral methylphenidate) and improvement in processing speed after 4 weeks of treatment with oral methylphenidate. The Perceptual organization and processing speed index is measured from the Digit Symbol and Symbol Searches from the Weschler Adult Intelligence Scale (WAIS-IV). The tasks that comprise the PSI, (Coding, Symbol Search), are timed and require attending to visual material, visual perception and organization, visual scanning, and hand-eye coordination. It is a standardized scale were 100 is the mean of a normal population, and each 10 points represents 1 standard deviation above or below the mean. Thus, an index of 110 is 1 SD above the mean, 90 is 1 SD below the mean.

Outcome measures

Outcome measures
Measure
Open Label Methylphenidate Treatment
n=11 Participants
Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily. Methylphenidate: Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
Perceptual Organization and Processing Speed Index
89 score on a scale
Standard Deviation 10

Adverse Events

Open Label Methylphenidate Treatment

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Open Label Methylphenidate Treatment
n=11 participants at risk
Forced titration with methylphenidate up to a dose of 30 mg administered orally twice daily. Methylphenidate: Subjects will be treated with oral methylphenidate, using a forced titration up to a dose of 30 mg given twice daily for 4 weeks. At that point, the neuropsychologic tests are repeated.
Nervous system disorders
Insomnia
18.2%
2/11 • Number of events 11 • 4 weeks
Adverse events and serious adverse events were collected through structured questionnaires administered at the last study visit.

Additional Information

Ramon Diaz-Arrastia

University of Pennsylvania

Phone: 215-662-9732-

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place